Correction to : Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy
| Errataetall: |
ErratumFor: J Hematol Oncol. 2021 Jul 5;14(1):106. - PMID 34225766 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Journal of hematology & oncology - 14(2021), 1 vom: 23. Sept., Seite 150 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Chunmeng [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 27.09.2021 published: Electronic ErratumFor: J Hematol Oncol. 2021 Jul 5;14(1):106. - PMID 34225766 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1186/s13045-021-01154-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM330978829 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM330978829 | ||
| 003 | DE-627 | ||
| 005 | 20231225212446.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13045-021-01154-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1103.xml |
| 035 | |a (DE-627)NLM330978829 | ||
| 035 | |a (NLM)34556168 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Chunmeng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Correction to |b Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 27.09.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ErratumFor: J Hematol Oncol. 2021 Jul 5;14(1):106. - PMID 34225766 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 650 | 4 | |a Published Erratum | |
| 700 | 1 | |a Shi, Fengxia |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yajing |e verfasserin |4 aut | |
| 700 | 1 | |a Dong, Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Xiang |e verfasserin |4 aut | |
| 700 | 1 | |a Tong, Chuan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yao |e verfasserin |4 aut | |
| 700 | 1 | |a Su, Liping |e verfasserin |4 aut | |
| 700 | 1 | |a Nie, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Weidong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of hematology & oncology |d 2008 |g 14(2021), 1 vom: 23. Sept., Seite 150 |w (DE-627)NLM180433709 |x 1756-8722 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2021 |g number:1 |g day:23 |g month:09 |g pages:150 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13045-021-01154-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2021 |e 1 |b 23 |c 09 |h 150 | ||